The former possibility has been widely accepted as correct, with little experimental substantiation, but both possibilities, in addition to generating active pepsin, account for the number of activation peptides usually observed.
It should be possible to distinguish between them, if the active product could be trapped into an inactive complex as soon as it is formed. This would prevent further digestion of the entire activation segment in case (1) and further activation in case (2), so that it should be possible to isolate in case (1) the intact activation segment, whereas in case (2) a smaller peptide, such as peptide a, should be recovered.
The complete sequence of pig pepsinogen is known (Stepanov et al., 1973; Sepulveda et al., 1975) and the activation segment sequence (residues 1 44)is:
Pepstatin does not bind to pepsinogen at pH values between 2.5 and 5 (J. Kay & C. W. Dykes, unpublished work) , but it is an extremely potent inhibitor of pepsin in the same pH range (Aoyagi et al., 1971 
Materials and Methods
Pig pepsinogen was purified to homogeneity from pig stomachs (Ryle, 1970 ) with afinal step ofchromatography on polylysine-Sepharose (Kay, 1972) . Pepstatin was given very generously by Professor H.
Umezawa.
Proteolytic activity measurements were made against haemoglobin at pH2 (Anson, 1948) and Azocoll at pH5.3 (Kay, 1975) . Activation experiments with pepstatin were performed by adding pepstatin (6.2mg/ml in methanol; 0.14ml) to 32ml of 3.2mM-HCl and mixing with a Vibramixer. This solution was cooled to 4°C and pepsinogen (36mg/ml in 4ml of water) was added (pepstatin/pepsinogen molar ratio 1.4:1). After being stirred for 2.5h at 4°C the mixture was spun in a bench centrifuge to remove a small amount (<1 %) of insoluble material. The supernatant was freeze-dried and the resultant powder was extracted (3 x 2ml) with 0.05M-sodium formate buffer, pH3.5. Most of the 'protein' was insoluble, whereas the supernatant contained mostly 'peptide'. The latter was applied to a polylysineSepharose column (1.8cmx 16cm) in 0.05M-formate buffer, pH 3.5.
Variations in the above conditions were performed
(1) by adding 0.09ml of pepstatin solution so that the pepstatin/pepsinogen molar ratio was 0.9: 1, and (2) by incubation in 0.05M-formate buffer, pH4.1.
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Results After activation of pepsinogen in the presence of pepstatin (pepstatin/pepsinogen molar ratio 1.4: 1), the freeze-dried material was extracted with formate buffer, giving an insoluble and a supernatant fraction.
(a) Insoluble mnterial
This was completely inactive against haemoglobin at pH2 and Azocoll at pH5.3. N-Terminal analysis with dansyl chloride showed both isoleucine and leucine, and polyacrylamide-gel electrophoresis at pH8.1 revealed two bands, one with a mobility similar to that of pepsinogen and the other major band with a mobility intermediate between those of pepsinogen and pepsin.
The amino acid composition is similar to the composition calculated from the sequence of residues 17-370 in pepsinogen (Table 1) .
When the pepstatin/pepsinogen molar ratio was lowered to 0.9:1, this insoluble 'protein' fraction had 10 % of the specific activity of pepsin against haemoglobin and Azocoll. The composition of this material, with pepsin for comparison, is also included in Table 1 .
(b) Supernatant
This was ciromatographed on polylysine-Sepharose at pH3.5. Peptides are not retarded on this column, which acts as a mixed affinity/ion-exchange resin for pepsinogen, pepsin and their derivatives (Kay, 1972) . A peptide fraction (A) passed unretarded through the column, and a second fraction (B) was eluted only on application of a linear NaCi gradient. Fraction B was found to be very similar to the insoluble material already described.
Samples of fraction A were taken for amino acid analysis and N-terminal analysis with dansyl chloride (Table 2) . The 'crude' compositions are similar to that calculated from the sequence of residues 1-16 in pepsinogen, and it seems to make little difference to the results whether the activation is performed above or below pH 3. The compositions show alanine and valine from the excess of pepstatin added, since this compound is not retarded either on polylysine--Sepharose. It has an acylated N-terminus and so is unreactive to dansyl chloride. The yield of 'crude' peptide obtained varied from batch to batch, being within 55-100% of the theoretical value.
After removal of the excess of pepstatin by chromatography on a Bio-Gel P2 column (1 cm x 100cm) in 0.5 %NH4HCO3, the purified peptide material had the composition: Lys showed the presence of one major basic peptide, but in both cases very faint additional spots could be detected with ninhydrin.
When the pepstatin/pepsinogen molar ratio was 0.9: 1, the composition of the 'crude' peptides obtained was much more similar to the expected composition from residues 1-44 (Table 2) . Several N-termini were observed, a result similar to that obtained on activation ofpepsinogen in the absence of pepstatin.
Discussion
No evidence in support of case (1) Thus it would seem that pepsinogen does not convert itselfinto pepsin in a one-step transformation, releasing the activation segment 1-44. By difference, it would appear that the alternative, progressive activation, scheme must be operative. Certainly the amino acid composition and N-and C-terminal analyses of the peptide fraction obtained on activation at a molar ratio of 1.4: 1 all suggest it to have been derived from residues 1-16 in the pepsinogen sequence.
The use of pepstatin to stop the activation, of course, precludes identification of the subsequent steps in the transformation. If the activation does proceed in a stepwise fashion, it is uncertain whether a limited number of discrete steps are involved or whether a 'ragged' activation at many susceptible peptide bonds could occur. The extra spots observed on electrophoresis and chromatography and the other faint N-termini suggest this could be so. Though most (90%) of the pepsinogen molecules have undergone proteolysis at the leucine-16-isoleucine-17 bond as the first step of activation, releasing peptide 1-16 as peptide a, it would seem that a small amount (<10%) may have undergone additional proteolysis within the 1-16 sequence.
It is noteworthy that a peptide from bovine pepsinogen, homologous to residues 1-16 from the pig protein, has been suggested (Harboe et al., 1974) to be the pepsin inhibitor peptide first mentioned by Herriott (1941) . It seems to make sense, from a control point of view, to have the first bond being hydrolysed on activation releasing the pepsin inhibitor so that it can exert its effect if required.
It could be argued that activation in the presence of a non-physiological molecule like pepstatin could alter the activation process. However, since only a very low molar excess was used and since such profound differences were found on increasing the ratio from 0.9: 1 to 1.4: 1, it would seem that such criticism is not valid. 
